Swept Source Enhanced Depth Imaging Optical Coherence Tomography (SS-EDI-OCT) and Study of the Retina, Choroid and Sclera in Health and Disease
试验速览
- 阶段
- 不适用
- 入组人数
- 120
- 主要终点
- Difference in chorio-retinal depth and morphology between healthy and diseased subjects
研究概览
简要总结
The investigators would be interested in applying the enhanced depth imaging technique to swept source optical coherence tomography, by modifying the acquisition protocol. Doing so, the investigators hope to improve the visualization of the choroid and perhaps even of the sclera.
详细描述
A structurally and functionally normal choroidal vasculature is essential for retinal function. The status of the choroid appears to be a crucial determinant in the pathogenesis of diseases such as age-related choroidal atrophy, myopic chorioretinal atrophy, central serous chorioretinopathy, chorioretinal inflammatory diseases, and tumors.
The in vivo structure of the choroid in health and disease is incompletely visualized with traditional imaging modalities, including indocyanine green angiography and ultrasonography.
Optical coherence tomography (OCT) is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. OCT is based on low-coherence interferometry. Nowadays, it is essential for managing retinal conditions.
Unfortunately, standard spectral domain optic coherence tomography (SD-OCT) is of limited use in imaging choroidal morphology.
A modification to the standard technique, termed enhanced depth imaging optical coherence tomography (EDI-OCT), is able to image the choroid with better clarity using commercial SD-OCTs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Ability to sit for OCT
排除标准
- •Media opacities precluding fundus view
研究组 & 干预措施
mydramide only
Patients in the clinics undergoing pupil dilation
Intervention:
Tropicamide instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon
干预措施: DRI-1 Swept source OCT, Atlantis, Topcon (Device)
control group
18-99 year old male + female
Intervention:
DRI-1 Swept source OCT, Atlantis, Topcon
干预措施: DRI-1 Swept source OCT, Atlantis, Topcon (Device)
mydramide and ephrine 10%
Patients in the clinics undergoing pupil dilation
Intervention:
Tropicamide and ephrine 10% instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon
干预措施: DRI-1 Swept source OCT, Atlantis, Topcon (Device)
All patients presenting with RD
Patients with retinal detachment
Intervention:
RD surgery DRI-1 Swept source OCT, Atlantis, Topcon
干预措施: DRI-1 Swept source OCT, Atlantis, Topcon (Device)
Impact of previous grid treatment
Patients after grid laser
Intervention:
DRI-1 Swept source OCT, Atlantis, Topcon
干预措施: DRI-1 Swept source OCT, Atlantis, Topcon (Device)
Effect of glaucoma medications
Patients requiring new intraocular presssur (IOP)-lowering treatment Patients with long-term IOP-lowering treatment
Intervention:
If needed, start of new IOP-lowering treatment DRI-1 Swept source OCT, Atlantis, Topcon
干预措施: DRI-1 Swept source OCT, Atlantis, Topcon (Device)
Effect of arteritic/non-arteritic AION
About 180 living patients diagnosed at ShaareZedek with anterior ischemic optic neuropathy (AION).
Longitudinal arm with newly diagnosed patients for 2 years follow-up
Intervention:
DRI-1 Swept source OCT, Atlantis, Topcon
干预措施: DRI-1 Swept source OCT, Atlantis, Topcon (Device)
NVAMD poorly responsive to Rx
Patients with neovascular age-related macular degeneration and epiretinal membreane/vitreomacular traction who do not respond to first course of Avastin
Intervention:
DRI-1 Swept source OCT, Atlantis, Topcon
干预措施: DRI-1 Swept source OCT, Atlantis, Topcon (Device)
Retrospective analysis
All patients pictured with DRI-OCT
Intervention:
DRI-1 Swept source OCT, Atlantis, Topcon
干预措施: DRI-1 Swept source OCT, Atlantis, Topcon (Device)
结局指标
主要结局
Difference in chorio-retinal depth and morphology between healthy and diseased subjects
时间窗: 2 years
次要结局
未报告次要终点